Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
Stanislas Quesada(Institut de Recherche en Cancérologie de Montpellier), Pascal Pujol(Centre National de la Recherche Scientifique), Anna DeFazio(The University of Sydney), Massimo Barberis(European Institute of Oncology), Xiaohua Wu(Fudan University Shanghai Cancer Center), Ignace Vergote(KU Leuven), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ana Oaknin(Hebron University), Xavier Matías‐Guiu(Universitat de Lleida), Éric Pujade-Lauraine(Eau de Paris (France)), Isabelle Ray‐Coquard(Centre Léon Bérard), Toon Van Gorp, Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Aleš Ryška(Charles University), Iain A. McNeish(Imperial College London), Étienne Rouleau(Inserm), Nicoletta Colombo(University of Milano-Bicocca), Angélica Nogueira‐Rodrigues(Eastern Cooperative Oncology Group), Robert L. Coleman(Texas Oncology), Frédérique Penault–Llorca(Inserm), Wilko Weichert(Deutsches Konsortium für Translationale Krebsforschung)
Cited by 19
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k